Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Media Sentiment Analysis For Acorda Therapeutics, Inc. (ACOR)

|Includes:Acorda Therapeutics, Inc. (ACOR)

Based on an analysis of recent news headlines, it appears that investors have mixed opinions about Acorda Therapeutics, Inc., especially when compared to its industry competitors.

Table Summary: Sentiment Analysis of Recent Headlines

  ACOR Biotech
% Positive Headlines 17.91 30
% Negative Headlines 13.43 21
% Neutral Headlines 68.66 49

Sample of Recent Headlines Processed by Our Sentiment Algorithms, Classified as Positive (Access Stock Sentiment Analysis Here)

  • Acorda Therapeutics' nasal spray for epilepsy shows positive Phase 1 results
  • Biogen, Acorda MS drug has conditional European OK
  • Acorda jumps 16% on EU nod for MS drug
  • Acorda says preliminary efficacy measures show GGF2 improves heart function

Sample of Recent Headlines Processed by Our Sentiment Algorithms, Classified as Negative (Access Stock Sentiment Analysis Here)

  • Acordas Cohen Says Sequestration Delaying New Drugs (Audio)
  • Acorda CEO Cohen on U.S. Budget Cuts, Research
  • Acorda, Biogen fall on EU drug rejection
  • Zacks Sell List Highlights: General Cable, Ternium, Acorda Therapeutics and Amsurg
  • InPlay: Acorda Therapeutics: Data from first clinical trial of GGF2 in heart failure presented at the American College of Cardiolo...
  • Earnings Miss at Acorda

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Stocks: ACOR